Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.
Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL.
Mote PA, et al. Among authors: howe c.
Breast Cancer Res Treat. 2015 Jun;151(2):309-18. doi: 10.1007/s10549-015-3397-0. Epub 2015 Apr 28.
Breast Cancer Res Treat. 2015.
PMID: 25917868